Rockefeller Financial Services Inc. raised its position in Inogen, Inc (NASDAQ:INGN) by 5.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,755 shares of the medical technology company’s stock after buying an additional 15,377 shares during the period. Rockefeller Financial Services Inc.’s holdings in Inogen were worth $29,557,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of Inogen by 0.4% in the first quarter. Wells Fargo & Company MN now owns 284,437 shares of the medical technology company’s stock worth $22,062,000 after buying an additional 1,158 shares during the period. State of Alaska Department of Revenue raised its stake in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Inogen by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the medical technology company’s stock worth $512,000 after buying an additional 200 shares during the period. Bank of Montreal Can raised its stake in shares of Inogen by 66.4% in the first quarter. Bank of Montreal Can now owns 68,085 shares of the medical technology company’s stock worth $5,280,000 after buying an additional 27,162 shares during the period. Finally, Peregrine Capital Management LLC raised its stake in shares of Inogen by 4.9% in the first quarter. Peregrine Capital Management LLC now owns 397,789 shares of the medical technology company’s stock worth $30,510,000 after buying an additional 18,543 shares during the period.
Shares of Inogen, Inc (INGN) traded down 0.08% during trading on Tuesday, hitting $94.52. The stock had a trading volume of 52,095 shares. Inogen, Inc has a 1-year low of $49.60 and a 1-year high of $97.71. The stock’s 50-day moving average price is $89.48 and its 200 day moving average price is $76.19. The firm has a market capitalization of $1.95 billion, a P/E ratio of 84.54 and a beta of 1.04.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, May 9th. The medical technology company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.15. Inogen had a return on equity of 11.67% and a net margin of 9.32%. The business had revenue of $52.50 million during the quarter, compared to analyst estimates of $49.06 million. During the same quarter in the prior year, the business posted $0.12 EPS. Inogen’s revenue for the quarter was up 22.1% compared to the same quarter last year. On average, analysts anticipate that Inogen, Inc will post $1.09 earnings per share for the current year.
A number of analysts have issued reports on the company. Needham & Company LLC raised their target price on Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 9th. Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. J P Morgan Chase & Co raised their target price on Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Stifel Nicolaus raised their target price on Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Finally, Sidoti assumed coverage on Inogen in a research report on Tuesday, April 18th. They issued a “neutral” rating and a $79.00 target price for the company. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $91.60.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of the stock in a transaction on Friday, June 16th. The stock was sold at an average price of $91.54, for a total value of $228,850.00. Following the completion of the sale, the executive vice president now owns 4,833 shares in the company, valued at approximately $442,412.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Alison Bauerlein sold 6,666 shares of the stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $83.24, for a total value of $554,877.84. Following the completion of the sale, the executive vice president now owns 25,758 shares of the company’s stock, valued at approximately $2,144,095.92. The disclosure for this sale can be found here. Insiders sold a total of 81,348 shares of company stock valued at $7,095,001 in the last quarter. 5.31% of the stock is currently owned by company insiders.
About Inogen
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
